ACPU
CNCE

Arrowgrass Capital Partners (US)’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-147,568
Closed -$2.23M – 576
2015
Q1 		$2.23M Buy
+147,568
New +$2.06M 0.03% 244

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s CNCE Position: Q2 2015 in Review

Arrowgrass Capital Partners (US) sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2015, closing a stake of 147,568 shares — an estimated $2.23M sold.

Arrowgrass Capital Partners (US) first reported a position in CNCE in Q1 2015 and held it in 1 quarter. The position peaked at $2.23M in Q1 2015. 67 funds tracked by Wall St. Rank hold CNCE as of Q2 2015.

  • Arrowgrass Capital Partners (US) reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 147,568 Concert Pharmaceuticals, Inc. shares in Q2 2015, an estimated $2.23M.
  • Arrowgrass Capital Partners (US) first reported a position in Concert Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Arrowgrass Capital Partners (US)'s Concert Pharmaceuticals, Inc. position peaked at $2.23M in Q1 2015.
  • 67 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q2 2015, filed 14 Aug 2015.